Dietary Supplements

The U.S. dietary supplement industry commends FDA for taking action to protect consumers by calling out marketers who make illegal and unsubstantiated drug claims related to COVID-19.

In this newly created role, Dr. Troup will lead strategy development and direct CHPA’s work on dietary supplements issues, evaluating science, shaping policy, and collaborating with stakeholders for this important, growing consumer health category.

The types of evidence used to monitor dietary supplement safety, including adverse event reports, emergency room visits and poison control center data.

The four leading trade associations representing the dietary supplement industry are concerned that some marketers of dietary supplements may be promoting them with claims of prevention or treatment of Coronavirus.

CHPA today applauds the U.S. Food and Drug Administration for enforcing existing provisions in the Federal Food, Drug, and Cosmetic Act by sending warning letters to 15 companies illegally marketing cannabidiol products.

Today CHPA submitted a citizen petition to the U.S. Food and Drug Administration urging the agency to exercise its existing statutory authority to swiftly issue regulations that establish a clear pathway for manufacturers to lawfully market cannabidiol in dietary supplements. 

This week, the four leading trade associations representing the U.S. dietary supplement industry joined forces to urge Congress to take action to ensure consumer safety and provide legal clarity in the CBD product marketplace.

Modernizing food and dietary supplement labels is in the best interest of consumers and industry alike. Supplement facts labels serve as a trusted source of information and provide a consistent way to comprehend nutrient content.